




1 Article

2 Evaluation of a new survivin ELISA and UBC® Rapid

3 for the detection of bladder cancer in urine

- 4 Jan Gleichenhagen^{1*}, Christian Arndt², Swaantje Casjens¹, Carmen Meinig¹, Holger Gerullis³,
- 5 Irina Raiko¹, Thomas Brüning¹, Thorsten Ecke⁴ and Georg Johnen¹

6 Supplementary Materials




7

9

10

Supplementary Figure S1. Comparison of different survivin assays. Obtained OD values from two commercial assays (R&D, ENZO) and the new ELISA (IPA) are plotted as signal to noise ratio (S/N) and interpolated by four-parameter logistic curve fitting.

11




1213

Supplementary Figure S2. Comparison of values for low-grade and high-grade tumors. (a) Survivin and (b) UBC® *Rapid*.


15

14


16 17



Supplementary Figure S3. Scatterplot of UBC® *Rapid versus* survivin. The plot shows marker concentrations of the (a) tumor group (rs = 0.38) and (b) clinical control group (rs = 0.19). CI = 95% confidence interval



Supplementary Figure S4. Venn diagram of high-grade tumors. Detected (left) and undetected (right) tumor cases by UBC® *Rapid* (cut-off 10 mg/l) and survivin (cut-off 0.033 ng/ml).



Supplementary Figure S5. ROC analyses of high-grade tumors and clinical controls for survivin (AUC = 0.88), UBC® *Rapid* (AUC = 0.88), and the combination (AUC = 0.91).